Skip to content

Study · Randomized controlled trial · n = 1,554 · 2008

3 results

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR

European urology15 Jan 2008Cited by 142 (Europe PMC)

PMID18243498 (opens in a new tab)DOI10.1016/j.eururo.2008.01.021 (opens in a new tab)PepBankPUB-18243498
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, cardiovascular mortality was 5.9% with longer-term goserelin versus 4.8% with short-term goserelin (p=0.16).

    In plain wordsIn men with prostate cancer, cardiovascular mortality did not significantly differ between longer-term and short-term goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeCardiovascular mortality at 5 years
    Study

    n = 1,554

    Comparator
    Short-term goserelin
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Cardiovascular mortality at 5 years
    5.9%
    longer-term adjuvant goserelin
    Cardiovascular mortality at 5 years
    4.8%
    short-term goserelin
    Gray's p
    0.16 unitless
    cardiovascular mortality at 5 years

    Source sentences

    Summary
    At 5 yr, cardiovascular mortality for men receiving longer-term adjuvant goserelin was 5.9% versus 4.8% with short-term goserelin (Gray's p=0.16).
    1 context sentence
    Summary · context
    From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-4, prostate-specific antigen [PSA] <150 ng/ml) received RT and 4 mo of goserelin and then were randomized to no additional therapy (arm 1) or 24 mo adjuvant goserelin (arm 2) in a phase 3 trial (Radiation Therapy Oncology Group [RTOG] 92-02).
  2. 02HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, longer goserelin treatment did not significantly increase cardiovascular mortality risk (adjusted HR=1.09; 95% CI, 0.81-1.47; p=0.58).

    In plain wordsIn men with prostate cancer, adjusted cardiovascular mortality risk did not significantly differ between longer-term and short-term goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeAdjusted cardiovascular mortality risk
    Study

    n = 1,554

    Comparator
    Short-term goserelin
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Adjusted hazard ratio, cardiovascular mortality
    1.09 HR
    longer-term vs short-term goserelin
    95% CI, adjusted HR
    0.81 to 1.47 HR
    longer-term vs short-term goserelin
    P value
    0.58 unitless
    adjusted HR, longer-term vs short-term goserelin

    Source sentences

    Summary
    In multivariate analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR]=1.09; 95% confidence interval [CI], 0.81-1.47; p=0.58; when censoring at time of salvage goserelin, HR=1.02, 95%CI, 0.73-1.43; p=0.9).
    1 context sentence
    Summary · context
    From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-4, prostate-specific antigen [PSA] <150 ng/ml) received RT and 4 mo of goserelin and then were randomized to no additional therapy (arm 1) or 24 mo adjuvant goserelin (arm 2) in a phase 3 trial (Radiation Therapy Oncology Group [RTOG] 92-02).
  3. 03HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, treatment arm did not significantly affect cardiovascular mortality when censored at salvage goserelin (HR=1.02; 95%CI, 0.73-1.43; p=0.9).

    In plain wordsIn men with prostate cancer, cardiovascular mortality did not significantly differ between treatment durations when analysis censored salvage goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeCardiovascular mortality risk with salvage censoring
    Study

    n = 1,554

    Comparator
    Short-term goserelin
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · 24 months additional goserelinAs given in this study (human).

    Measurements

    Hazard ratio, cardiovascular mortality, censored at salvage goserelin
    1.02 HR
    longer-term vs short-term goserelin
    95% CI, HR censored at salvage goserelin
    0.73 to 1.43 HR
    longer-term vs short-term goserelin
    P value
    0.9 unitless
    HR censored at salvage goserelin

    Source sentences

    Summary
    In multivariate analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR]=1.09; 95% confidence interval [CI], 0.81-1.47; p=0.58; when censoring at time of salvage goserelin, HR=1.02, 95%CI, 0.73-1.43; p=0.9).
    1 context sentence
    Summary · context
    From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-4, prostate-specific antigen [PSA] <150 ng/ml) received RT and 4 mo of goserelin and then were randomized to no additional therapy (arm 1) or 24 mo adjuvant goserelin (arm 2) in a phase 3 trial (Radiation Therapy Oncology Group [RTOG] 92-02).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00767286

Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Radiation Therapy Oncology GroupCompletion Nov 2003

Prostate Cancer

Trial pageClinicalTrials.govUpdated 28 Jan 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.